DEF: Cadrenal Therapeutics Announces 2025 Annual Stockholders Meeting Agenda

Cadrenal Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on September 24, 2025, to vote on the election of a Class III director and the ratification of its independent registered public accounting firm.

Summary

• The 2025 Annual Meeting of Stockholders for Cadrenal Therapeutics, Inc. will be held virtually on Wednesday, September 24, 2025, at 10:00 a.m. Eastern Time via live webcast.
• Stockholders will vote on two key proposals: the election of Steven Zelenkofske as the Class III director for a three-year term expiring at the 2028 Annual Meeting, and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The record date for determining stockholders entitled to vote is July 28, 2025, with 2,046,854 shares of Common Stock outstanding.
• The Board of Directors unanimously recommends a 'FOR' vote for both the director nominee and the auditor ratification proposal.
• The meeting format is a live audio webcast, with no physical in-person attendance, and stockholders can submit questions in advance online until September 23, 2025.

Sentiment

Score: 5

Explanation: The filing is a standard, procedural proxy statement for an annual meeting, presenting routine corporate governance matters without significant positive or negative operational or financial news. The sentiment is neutral as expected for this type of document.

Positives

• The Board of Directors recommends a 'FOR' vote for both the director nominee and the auditor ratification, indicating internal alignment and confidence.
• The company is utilizing an SEC rule to furnish proxy materials over the internet, aiming to reduce environmental impact and lower printing and distribution costs.
• A majority of the Board of Directors consists of independent directors (John R. Murphy, Dr. Steven Zelenkofske, and Dr. Glynn Wilson), enhancing corporate governance and oversight.
• The Audit Committee, composed entirely of independent directors, has confirmed the independence of WithumSmith+Brown, PC as the independent registered public accounting firm.
• The company has adopted a comprehensive Code of Business Conduct and Ethics applicable to all officers, directors, and employees, promoting ethical conduct.
• An insider trading policy is in place, prohibiting short-term trading, short sales, options trading, hedging, and pledging of company securities by directors, officers, and employees.
• A clawback policy has been adopted, allowing the company to recover performance-based compensation from executive officers in the event of an Accounting Restatement due to material noncompliance with financial reporting requirements.

Risks

• The limitation of liability and indemnification provisions for directors and officers may discourage stockholders from initiating lawsuits for breaches of fiduciary duties, potentially reducing the likelihood of derivative litigation even if beneficial to the company and stockholders.
• Indemnification for liabilities arising under the Securities Act of 1933, as amended, is considered against public policy by the SEC and is therefore unenforceable.

Future Outlook

The company's 2022 Successor Equity Incentive Plan includes an evergreen provision, automatically increasing the maximum number of shares available for issuance annually on January 1st until 2033, based on outstanding shares and warrants. This ensures a continuous pool of equity for future compensation and incentives.

Management Comments

• "On behalf of the Board of Directors and the employees of Cadrenal Therapeutics, Inc., we thank you for your continued support and look forward to speaking with you at the 2025 Annual Meeting." Quang X. Pham, Chairman and Chief Executive Officer.

Industry Context

This filing is a standard proxy statement, primarily focused on corporate governance and procedural matters for the upcoming annual meeting. It does not provide specific insights into broader industry trends or competitive landscape beyond the general context of the company operating in the biotech and pharmaceutical space.

Management Changes

Corporate Governance

Related Party Transactions

• Employment agreements with Chief Executive Officer Quang X. Pham, Chief Financial Officer Matthew Szot, Chief Operating Officer Jeffrey Cole, and Chief Medical Officer James Ferguson, detailing their compensation, including salaries, bonuses, and severance terms.
• A severance agreement with former Chief Medical Officer Douglas Losordo, outlining his severance package.
• The PVBQ Living Trust, where Quang X. Pham serves as trustee and his child is the beneficiary, beneficially owns 200,000 shares of Common Stock, representing 9.77% of outstanding shares.

Stakeholder Impact

• Shareholders: Will participate in key corporate governance decisions, including the election of a director and ratification of the auditor. The virtual meeting format and online proxy materials aim to provide convenient access and reduce costs.
• Employees: Subject to the company's Code of Business Conduct and Ethics, Insider Trading Policy, and Clawback Policy, promoting ethical conduct and compliance. Executive officers' compensation and employment terms are detailed.
• Directors and Officers: Subject to specific compensation structures, indemnification provisions, and limitations on liability, designed to attract and retain qualified individuals while adhering to governance standards.

Next Steps

• Stockholders are encouraged to vote on the election of Steven Zelenkofske as Class III director and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for fiscal 2025.
• The company intends to announce preliminary voting results at the 2025 Annual Meeting and publish final results in a Current Report on Form 8-K within four business days.
• Stockholders planning to present proposals for inclusion in the 2026 proxy materials under SEC Rule 14a-8 must submit them by April 2, 2026.
• Stockholders intending to present proposals or director nominations at the 2026 Annual Meeting (not for inclusion in proxy materials) must provide written notice between May 27, 2026, and June 26, 2026.
• Stockholders intending to solicit proxies for director nominees other than Cadrenal nominees must provide notice by July 26, 2026.

Key Dates

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, Stockholder Vote, Cadrenal Therapeutics, CVKD